A thymoma dramatically responded to PSL by Hanibuchi, Masaki et al.
396
CASE REPORT
A rare case of invasive thymoma presented a dramatic response 
to low-dose prednisolone as a single-drug therapy.
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Abstract : A 76-year-old woman with a history of angina pectoris, hypertension and dyslipidemia was pointed out 
an abnormal opacity in the right hilar region on routine chest X-ray. Chest computed tomography showed mass-
es in the anterior mediastinum with the invasion of the adjacent ascending aorta, right brachiocephalic vein and 
right pleura. Histologic examination led to a diagnosis of Masaoka stage IVa thymoma. Three courses of chemo-
therapy were given, but further tumor progression was seen. Thereafter, the patient was followed without ag-
gressive treatments. One year after the initial diagnosis, she presented with dyspnea and right chest pain. Chest 
CT revealed right massive pleural effusion with pleural dissemination and much further progression of existing 
tumors. For the purpose of symptom palliation, a low dose (5 mg / day) of prednisolone was commenced, which 
unexpectedly led to marked alleviation of patient’s symptoms and dramatic decrease of pleural effusion. To the 
best of our knowledge, this is the first report of an invasive thymoma responded to low-dose corticosteroid. The 
present case suggests that corticosteroids, even at low doses, might be potentially effective for invasive thymoma 
after failure of surgery, chemotherapy and radiotherapy. J. Med. Invest. 68 : 396-399, August, 2021
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INTRODUCTION
 
Thymoma is the most common tumor of the anterior mediasti-
num, and arises from thymic epithelial cells with non-neoplastic 
T lymphocytes at varying degrees (1, 2). Surgical resection has 
been advocated as the primary treatment of thymoma, since it is 
often found well encapsulated (3, 4). In patients with advanced 
diseases or a recurrence after primary therapy, systemic chemo-
therapy can be considered (5). It has been reported that moderate 
to high doses of corticosteroids including steroid pulse therapy as 
a single-drug treatment also induced regression of thymoma (6-
9). Kobayashi et al. demonstrated that the steroid pulse therapy 
induced tumor regression in 8 of 17 (47.1%) patients with ad-
vanced thymoma and that the reduction in tumor size was most 
prominent in World Health Organization (WHO) classification, 
type B1 thymomas compared with type B3 (10). Although the 
pro-apoptotic effects are considered to play an important role 
in the growth-inhibiting action (11), the significance and the 
optimal dose of corticosteroid therapy in patients with thymoma 
is poorly understood.
In this report, we demonstrated a patient who had Masaoka 
clinical stage IVa invasive thymoma (WHO classification, type 
B3) complicated with massive pleural effusion and pleural dis-
semination, which remarkably responded to low-dose predniso-
lone (PSL). 
CASE REPORT
A 76-year-old woman with a history of angina pectoris, hyper-
tension and dyslipidemia was pointed out an abnormal opacity 
in the right hilar region on routine chest X-ray. Chest computed 
tomography (CT) showed masses in the anterior mediastinum 
adjacent to the ascending aorta, right brachiocephalic vein and 
right pleura. These findings contraindicated curative surgery. 
A partial resection was performed and a diagnosis of Masaoka 
clinical stage IVa thymoma with the invasion of surrounding 
organs, such as right brachiocephalic vein, right internal tho-
racic vein, right mediastinum, right lung and pleura, was made. 
A histologic examination revealed that tumors were composed 
mainly of epithelial cells showing squamoid features and focal 
mild atypia with scant lymphocytes (WHO classification, type 
B3 thymoma). The positivity of Ki-67 was 20-30% in atypical 
epithelial cells. After diagnosis, three courses of chemotherapy 
(carboplatin and paclitaxel) were given, but a mass adjacent 
to the ascending aorta further enlarged. Although alternative 
chemotherapies were recommended, she refused the proposal. 
Thereafter, the patient was referred to our hospital for sup-
portive care and palliative treatments of invasive thymoma six 
months after the initial diagnosis.
At the initial admission to our hospital, she did not complain 
of any respiratory symptoms and her general condition was 
relatively good. The physical examinations revealed body tem-
perature of 36.3 ℃, blood pressure of 113 / 63 mmHg, pulse of 59 
beats per minute and percutaneous oxygen saturation of 97% on 
room air. The remainder of the physical examinations was also 
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normal including chest auscultation. Muscle weakness was not 
recognized. The laboratory findings showed mild leukocytopenia 
and anemia. The serum level of human chorionic gonadotropin 
was within normal range and the acetylcholine receptor anti-
body was negative. The remainder of laboratory test results is 
shown in Table 1. We continued to follow the patient without 
aggressive treatments.
One year after the initial diagnosis, she presented with dys-
pnea and right chest pain. Chest CT revealed right massive 
pleural effusion and much further progression of existing tumors 
(Figure 1). Although the cytology of pleural effusion was negative 
(class II), we considered the etiology of pleural effusion as pleural 
Figure 1.　Chest X-ray and Chest CT findings before corticosteroid treatment.
Right massive pleural effusion and mass shadow in the right upper mediastinum was evident in chest X-ray (Figure 1A). Chest 
CT revealed right massive pleural effusion and tumors in the right hilum, anterior mediastinum, and right pleura (Figure 1B).
Table 1.　Laboratory data at the first admission
Hematology Biochemistry
WBC 3,400 / μL AST 25 IU / L BS 98 mg / dL
  Neu   62.8 % ALT 16 IU / L HbA1c (NGSP) 5.8 %
  Lymph 29.5 % ALP 192 U / L BNP 26.3 pg / mL
  Mono 5.9 % LDH 159 IU / L PT 11.8 secs
  Eos 1.2 % γ-GTP 27 U / L PT activity 100 %
  Baso 0.6 % CK 87 U / L APTT 27.8 secs
RBC 324×104 / μL T-bil 0.5 mg / dL CEA 1.3 ng / mL
Hb 11.1 g / dL TP 7.5 g / dL CYFRA 21-1 3.4 ng / mL
Ht  32.3 % Alb 4.2 g / dL hCG 4.4 mIU / mL
Plt 17.6×104 / μL T-cho 130 mg / dL Anti-Ach-R Ab < 0.2 nmol / L
Amy 115 IU / L
BUN 16.3 mg / dL
Cre 0.53 mg / dL
Na 143 mEq / L
K 3.9 mEq / L
Cl 107 mEq / L
Ca 9.6 mg / dL
CRP 0.05 mg / dL
BNP, brain natriuretic peptide ; CEA, carcinoembryonic antigen ; CYFRA 21-1, cytokeratin fraction 21-1 ; hCG, human chorionic 
gonadotropin ; Anti-Ach-R Ab, anti-acetylcholine receptor antibody
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dissemination of invasive thymoma. Thoracentesis, and palli-
ative radiation therapy to the right hilum, apex and chest wall 
temporarily alleviated her symptoms. Thoracic cavity drainage 
by the chest drainage tube and pleurodesis were not performed 
following the patient’s wishes. Even after that, thoracenteses 
were performed as appropriate and supportive treatment for 
bilateral pretibial and foot-pad edema, such as anti-diuretics, 
were commenced, however, pleural effusion gradually increased 
and her symptoms, such as dyspnea and general fatigue got 
worse. For symptom palliation, we started a low dose (5 mg / day) 
of PSL. As her body weight was 46.7 kg, the dose of PSL was 
approximately 0.1 mg / kg / day at the treatment initiation. Unex-
pectedly, her symptoms markedly improved and pleural effusion 
dramatically decreased on chest X-ray at three-weeks after corti-
costeroid initiation. Chest CT also showed significant reduction 
of right pleural effusion and regression of tumors in the right 
hilum and pleura (Figure 2). The general condition and right 
pleural effusion of the patient remain well-controlled even now 
while continuing to receive 4 mg / day of PSL at six-months after 
corticosteroid initiation. No adverse events have been reported 
during treatment, with the exception of mild insomnia.
DISCUSSION
Corticosteroids are known to induce regression of thymoma, 
whereas these are often administered to patients with thymoma 
to treat associated symptoms of myasthenia gravis (6) and pure 
red-cell aplasia (12) rather than the tumor itself. There has been 
a small number of single case reports of response to corticoste-
roids alone in patients with thymoma, mostly after failure of 
combined chemoradiotherapy and surgery (6-8). In these reports, 
moderate to high doses of corticosteroids including steroid pulse 
therapy (more than 30 mg / day of PSL) were administered, how-
ever, there is no report describing therapeutic efficacy of low-dose 
corticosteroid in patients with invasive thymoma. To the best of 
our knowledge, this is the first report of an invasive thymoma 
presented a dramatic response to low-dose corticosteroid as a 
single-drug therapy.
Since the first description of regression of thymoma by the 
treatment of adrenocorticotropic hormone (13), several reports 
have indicated that corticosteroids might be potentially effective 
for invasive thymoma (7, 14), primarily in cases of lymphocytic 
thymoma, and have been attributed to the apoptotic effects of 
corticosteroids, mainly on the lymphocytic component of the 
tumor (8, 12). On the other hand, glucocorticoid receptor (GR) 
is shown to be expressed on neoplastic thymic epithelial cells as 
well as on non-neoplastic thymocytes and lymphocytes in thy-
moma. Glucocorticoids induced apoptosis via G1 cell cycle arrest 
of thymic epithelial cells, indicating that glucocorticoids directly 
suppressed in vitro proliferation of GR-positive neoplastic thymic 
epithelial cells (15). In addition, studies to evaluate histopatho-
logic changes of thymoma preoperatively treated with high doses 
of corticosteroids, such as steroid pulse therapy, demonstrated 
apoptosis induction in neoplastic thymic epithelial cells, as well 
as lymphocytes in the specimens resected after corticosteroid 
treatment (9, 10). These findings suggested that corticosteroids 
cause degenerative changes in neoplastic thymic epithelial cells, 
as well as lymphocytes in thymoma.
The association of therapeutic efficacies of corticosteroid 
with histological subtypes of thymoma remains controversial. 
Kobayashi et al. demonstrated that the steroid pulse therapy 
induced tumor regression in patients with advanced thymoma 
and that the tumor reduction was most prominent in type B1 
thymoma (also known as lymphocytic thymoma) compared with 
type B3 thymoma (also known as epithelial thymoma) (10). 
Moreover, glucocorticoids directly suppressed the proliferation 
of GR-positive neoplastic thymic epithelial cells via the induction 
of apoptosis (15), and the numbers of GR sites were reported 
to be much greater in lymphoepithelial thymoma as compared 
to those in pure epithelial thymoma (16). These observations 
support a hypothesis that lymphocytic component of thymoma 
Figure 2.　Chest X-ray and Chest CT at six-months after corticosteroid initiation.
Right pleural effusion dramatically decreased and the shrinkage of tumor in the right upper mediastinum also observed in 
chest X-ray (Figure 2A). Chest CT showed significant reduction of right pleural effusion and regression of tumors in the right 
hilum and pleura (Figure 2B).
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is more responsive to corticosteroid treatment. At the other 
extreme, Hu et al. reported that glucocorticoid therapy induced 
thymoma regression in 11 of 13 cases, regardless of different 
histologic findings (17). In addition, it is shown that high doses of 
corticosteroids, such as steroid pulse therapy, induced apoptosis 
of neoplastic thymic epithelial cells, as well as lymphocytes in 
thymoma (9). In the present case, although we could not evaluate 
the pathological change after treatment, corticosteroid therapy, 
even at low doses, might affect not only lymphocytic components 
but also neoplastic thymic epithelial cells in WHO classification, 
type B3 thymoma.
In terms of the prognostic markers for thymoma, the his-
tological subtype is considered to be a promising candidate. 
However, previous study to examine the histopathologic features 
of pretreatment biopsies and posttreatment surgical specimens 
of thymoma demonstrated the significant changes of the histo-
logical subtypes after treatment including corticosteroids (9). 
As the conversion of histological subtype might affect the ther-
apeutic response and the clinical course, it is possible that the 
pretreatment histopathologic features do not necessarily reflect 
the prognosis of thymoma. Recently, Mimae et al. reported that 
GR revealed a high rate of expression (82.9%) in thymomas and 
thymic carcinomas. Multivariate analysis demonstrated that 
GR expression was associated with better prognosis in patients 
with surgically resected thymomas and thymic carcinomas (18). 
Moreover, Kobayashi et al. showed that the reduction in tumor 
size after steroid pulse therapy was accompanied with a marked 
reduction in the CD4+8+ double-positive immature lymphocytes 
(10), and indicated that tumor size reduction of thymomas was 
partly explained by the reduction in the bulk of these lym-
phocytes. Thus, GR expression and CD4+8+ double-positive 
immature lymphocytes might be new promising candidates as 
prognostic markers for thymoma. However, abovementioned ob-
servations need to be interpreted cautiously, because the sample 
size in each study was quite limited. Further large-scale studies 
would be required to show the more clinically significant data in 
the future.
In conclusion, we herein reported a rare case of invasive thy-
moma presented a dramatic response to low-dose corticosteroid 
as a single-drug therapy. Five mg / day of PSL that used for the 
purpose of symptom palliation markedly alleviated patient’s 
symptoms and pleural effusion dramatically decreased. To the 
best of our knowledge, this is the first report of an invasive 
thymoma responded to low-dose corticosteroid. The present case 
suggests that corticosteroids even at low doses, as well as those 
at high doses, might be potentially effective for invasive thymo-
ma after failure of surgery, chemotherapy and radiotherapy.
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